Regulatory Focus™ > News Articles > 6 > Recon: J&J to Sell LifeScan Diabetes Unit in $2.1B Deal

Recon: J&J to Sell LifeScan Diabetes Unit in $2.1B Deal

Posted 13 June 2018 | By Ana Mulero 

Recon: J&J to Sell LifeScan Diabetes Unit in $2.1B Deal

In Focus: US In Focus: International
  • Royal Philips acquires the U.K.’s Remote Diagnostic Technologies for undisclosed price (Fierce)
  • Brexit warning sounded on EU public health system (pharmaphorum) (PharmaTimes)
  • Public back £21bn health spending boost for the NHS (The Times) (PharmaTimes)
  • For electronic medical device developers, here’s what you need to know about IEC 60601 standard (MedCity News)
  • Chinese-American Pharma Entrepreneur Joins Billionaire Ranks Via Shenzhen (Forbes)
  • EU endorses new measures to protect women from valproate epilepsy drug (Reuters)
  • 'We are still at war' with Ebola: WHO chief (Reuters)
  • Health payments are pushing people into poverty, even in high-income countries (WHO)
  • New trans-NIH consortium aims to advance pediatric research on a global level (NIH)
Pharmaceuticals & Biotechnology
  • Stepping into the pricing debate, FDA chief Scott Gottlieb proposes new reimbursement idea for antibiotics (Endpoints)
  • Biotech Executives Fret Over Hassles And Uncertainties Of 'Right To Try' (Forbes)
  • New preventive treatments for migraine (BMJ)
  • The Women’s Libido Pill Is Back, and So Is the Controversy (Bloomberg)
  • Studying sex differences will improve health for women and men (STAT)
  • Major opioids legislation is taking shape. Can it make a dent in a national epidemic? (STAT)
  • The trouble with those post-marketing studies required by the FDA (STAT-$)
  • Generic competition not a cure-all for high drug prices (Modern Healthcare)
  • Gilead veteran looks to move ahead in new role as startup CEO (MedCity News)
  • Trust pharma? Not so much, annual survey shows, with biggest loss ever (Fierce)
  • Celeb-happy Allergan adds Helen Hunt, Trista Sutter and more to Alzheimer's push (Fierce)
  • MEDNAX National Medical Group and Pacira Pharmaceuticals Launch National Enhanced Recovery after Cesarean Surgery (ERACS) Collaborative to Minimize Opioid Use (Press)
  • Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply (Press)
Pharmaceutical and Biotechnology: Study Results, Filings and Designations
  • FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for GARDASIL 9 in Women and Men Ages 27 to 45 for the Prevention of Certain HPV-Related Cancers and Diseases (Press)
  • vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study (Press)
  • Newron Provides Update on STARS Clinical Study with Sarizotan for the Treatment of Rett Syndrome (Press)
  • REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I (Press)
  • Autism Spectrum Disorder (ASD) "Fever Effect" Pilot Study Enrollment Announced (Press)
Medical Devices
  • Medicare Will Now Support CGM Smartphone App Use for Diabetes (Medscape)
  • Medtronic wins FDA nod for DBS clinician programmer (MassDevice) (Press)
  • FDA panel backs Cordis’ Incraft stent graft for abdominal aortic aneurysms (Fierce)
  • Intuitive Surgical backs lung cancer tech play Broncus (Fierce)
  • As Device Recalls Hit The Stratosphere, FDA Asks Firms To Keep A Sharp Eye On Quality Systems (Medtech Insight-$)
  • Rutgers Researchers Develop Automated Robotic Device For Faster Blood Testing (Rutgers Today)
  • Noble launches AdhereIT platform for self-injection training (DDBN)
  • Biogen launches new app, Aby, for patients with MS (MobiHealthNews)
  • The security risk storm is here: Medical device threats are real and a patient safety risk (Healthcare IT News)
  • Apple files patent for blood pressure monitoring device (Healthcare IT News)
  • Allergan's Fat-Freezing Unit Freed From False Ad Claims (Law360-$)
  • Zimmer NexGen MDL Nears Finish With Confidential Deal (Law360-$)
  • LEO Pharma A/S and FibroTx LLC Enter Partnership to Explore Non-Invasive Skin Test Technology (Press)
  • FDA Clears Gold Standard Diagnostics’ Borrelia burgdorferi IgG/IgM ELISA Assay (Press)
  • Agilent Companion Diagnostic Gains Expanded FDA Approval in Cervical Cancer (Press)
  • AdvaMed Statement on FDA Medical Device Communications Guidance (AdvaMed)
US: Assorted & Government
  • Trump administration is shutting down practice-guidelines clearinghouse for doctors (STAT)
  • Senior Justice Department attorney quits after Sessions rescinds defense of Obamacare (Axios)
  • House passes 25 bills to fight opioid addiction and overdoses (Washington Examiner)
  • GOP senator: DOJ's ObamaCare argument 'as far-fetched as any I've ever heard' (The Hill)
  • DEA, Nunc Pro Tunc Rulings, and Hearings That Never Happened (FDA Law Blog)
  • Drugmakers Denied Patient Info In Opioid MDL Bellwethers (Law360-$)
Upcoming Meetings & Events Europe
  • New funding to digitise info between health and social care (PharmaTimes)
  • NHS should employ robots to save time and money, suggests finds (PharmaTimes)
  • Spending on shortages of generics rose sevenfold last year to £315m (BMJ)
  • UK bank launches £2.5B plan to fund innovation, with a special place for its long-ailing biotech scene (Endpoints)
  • CleanCision System Earns CE Mark Approval (Press)
  • Janssen’s Tremfya (guselkumab) receives its first two positive Health Technology Assessments in Europe (Press)
  • Marketing authorisations granted in May 2018 (MHRA)
  • Marketing authorisations: lists of granted licences (MHRA)
  • The Policies of Hainan's Pharmaceutical and Healthcare Industry (Lexology)
  • What if South Korea supplies vaccines for North? (Korea Biomedical Review)
  • In Brief: South Korean Medical Device Information & Technology Assistance Center Changes Name (Emergo Group)
  • Pharma on recovery path becomes a darling of mutual funds (Economic Times)
  • Health spending pushed 55 million Indians into poverty in a year: Study (Times of India)
  • New report recommends digital health test beds to drive innovation in areas of greatest need (Healthcare IT News)
  • Guidance Document - Fees for the Right to Sell Drugs (Health Canada)
  • Summary - Cancellation of a Drug Identification Number (DIN) and Notification of the Discontinuation of Sales (Health Canada)
  • Many Canadians diagnosed with colorectal cancer too late, despite availability of screening (The Canadian Press)
  • ALECENSARO (alectinib) approved by Health Canada for first-line treatment of ALK-positive lung cancer (Press)
  • Medline Announces Expansion of Canadian Operations with Acquisition of Dufort et Lavigne Ltée  (Press)
General Health & Other Interesting Articles
  • I handed over my genetic data to the NIH. Here’s why you should, too (STAT)
  • Hiding My Depression Almost Destroyed My Job (Bloomberg)
  • More U.S. kids unvaccinated in states that allow non-medical exemptions (Reuters)
  • Survey: Hospitals' adoption of mobile strategies hits a snag (MobiHealthNews)
  • Four tips to help you fight back against high medical bills (CNBC)

Regulatory Reconnaissance is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory news stories from around the globe. Each weekday morning, we aim to bring you the latest highlights of new approvals, meetings, legal and political developments, regulations and guidance, and the latest trends with the potential to impact regulatory affairs professionals and the industry in which they work.

Need to contact the editor of Regulatory Reconnaissance? Email us at

A story's inclusion in Regulatory Reconnaissance does not imply endorsement by Regulatory Focus or RAPS.

Categories: Recon

Regulatory Focus newsletters

All the biggest regulatory news and happenings.